FRONTOTEMPORAL DEMENTIA - COMPREHENSIVE INSIGHTS INTO PATHOGENESIS, DIAGNOSIS, AND INNOVATIVE TREATMENTS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.6339Keywords:
Frontotemporal Dementia (FTD), Neurodegeneration, Primary Progressive Aphasia (PPA), Genetics, Biomarkers, Caregiver SupportAbstract
Frontotemporal dementia (FTD) is a clinically and genetically diverse group of neurodegenerative disorders predominantly affecting the frontal and anterior temporal lobes, leading to progressive changes in behavior, language, and executive function. FTD is the most common cause of young-onset dementia and third overall among degenerative dementias, with a prevalence of 15–22 per 100,000 and an incidence of 2.7–4.1 per 100,000. The core clinical syndromes include the behavioral variant (bvFTD), semantic and nonfluent primary progressive aphasias (svPPA, nfvPPA), and overlap with motor disorders such as progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Genetic mutations, especially C9orf72, GRN, and MAPT, are responsible for most familial cases and involve proteinopathies with TDP-43, tau, and FUS proteins. Biomarkers (e.g., neurofilament light chain, progranulin) and neuroimaging are used to improve detection and differentiate subtypes, although reliable biomarkers are lacking. Management is largely supportive, with a combination of non-pharmacological therapies (e.g., exercise, speech and occupational strategies, behavioral tactics, caregiver education) and pharmacotherapy for neuropsychiatric symptoms. Clinical trials explore gene therapies and disease-modifying drugs, indicating a move towards personalized medicine. Despite major advances, obstacles persist for early detection and effective therapies, underlining the need for sustained multidisciplinary research in FTD.
References
Snowden, J. S., Neary, D., & Mann, D. M. (2004). Autopsy proven sporadic frontotemporal dementia due to microvacuolar-type histology, with onset at 21 years of age. Journal of Neurology, Neurosurgery, and Psychiatry, 75(9), 1337–1339. https://doi.org/10.1136/jnnp.2003.028498
Gislason, T. B., Sjögren, M., Larsson, L., & Skoog, I. (2003). The prevalence of frontal variant frontotemporal dementia and the frontal lobe syndrome in a population based sample of 85 year olds. Journal of Neurology, Neurosurgery, and Psychiatry, 74(7), 867–871. https://doi.org/10.1136/jnnp.74.7.867
Onyike, C. U., & Diehl-Schmid, J. (2013). The epidemiology of frontotemporal dementia. International Review of Psychiatry, 25(2), 130–137. https://doi.org/10.3109/09540261.2013.776523
Erkkinen, M. G., Kim, M. O., & Geschwind, M. D. (2018). Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harbor Perspectives in Biology, 10(4), a033118. https://doi.org/10.1101/cshperspect.a033118
Moore, K. M., Nicholas, J., Grossman, M., McMillan, C. T., Irwin, D. J., Massimo, L., Van Deerlin, V. M., Warren, J. D., Fox, N. C., Rossor, M. N., Mead, S., Bocchetta, M., Boeve, B. F., Knopman, D. S., Graff-Radford, N. R., Forsberg, L. K., Rademakers, R., Wszolek, Z. K., van Swieten, J. C., Jiskoot, L. C., … FTD Prevention Initiative (2020). Age at symptom onset and death and disease duration in genetic frontotemporal dementia: An international retrospective cohort study. The Lancet. Neurology, 19(2), 145–156. https://doi.org/10.1016/S1474-4422(19)30394-1
Rascovsky, K., Hodges, J. R., Knopman, D., Mendez, M. F., Kramer, J. H., Neuhaus, J., van Swieten, J. C., Seelaar, H., Dopper, E. G., Onyike, C. U., Hillis, A. E., Josephs, K. A., Boeve, B. F., Kertesz, A., Seeley, W. W., Rankin, K. P., Johnson, J. K., Gorno-Tempini, M. L., Rosen, H., Prioleau-Latham, C. E., … Miller, B. L. (2011). Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain: A Journal of Neurology, 134(Pt 9), 2456–2477. https://doi.org/10.1093/brain/awr179
Cividini, C., Basaia, S., Spinelli, E. G., Canu, E., Castelnovo, V., Riva, N., Cecchetti, G., Caso, F., Magnani, G., Falini, A., Filippi, M., & Agosta, F. (2022). Amyotrophic lateral Sclerosis-Frontotemporal dementia: Shared and divergent neural correlates across the clinical spectrum. Neurology, 98(4), e402–e415. https://doi.org/10.1212/WNL.0000000000013123
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., Manes, F., Dronkers, N. F., Vandenberghe, R., Rascovsky, K., Patterson, K., Miller, B. L., Knopman, D. S., Hodges, J. R., Mesulam, M. M., & Grossman, M. (2011). Classification of primary progressive aphasia and its variants. Neurology, 76(11), 1006–1014. https://doi.org/10.1212/WNL.0b013e31821103e6
Bott, N. T., Radke, A., Stephens, M. L., & Kramer, J. H. (2014). Frontotemporal dementia: Diagnosis, deficits and management. Neurodegenerative Disease Management, 4(6), 439–454. https://doi.org/10.2217/nmt.14.34
Teichmann, M., Kas, A., Boutet, C., Ferrieux, S., Nogues, M., Samri, D., Rogan, C., Dormont, D., Dubois, B., & Migliaccio, R. (2013). Deciphering logopenic primary progressive aphasia: A clinical, imaging and biomarker investigation. Brain: A Journal of Neurology, 136(Pt 11), 3474–3488. https://doi.org/10.1093/brain/awt266
Chan, D., Anderson, V., Pijnenburg, Y., Whitwell, J., Barnes, J., Scahill, R., Stevens, J. M., Barkhof, F., Scheltens, P., Rossor, M. N., & Fox, N. C. (2009). The clinical profile of right temporal lobe atrophy. Brain: A Journal of Neurology, 132(Pt 5), 1287–1298. https://doi.org/10.1093/brain/awp037
Höglinger, G. U., Respondek, G., Stamelou, M., Kurz, C., Josephs, K. A., Lang, A. E., Mollenhauer, B., Müller, U., Nilsson, C., Whitwell, J. L., Arzberger, T., Englund, E., Gelpi, E., Giese, A., Irwin, D. J., Meissner, W. G., Pantelyat, A., Rajput, A., van Swieten, J. C., Troakes, C., … Movement Disorder Society-endorsed PSP Study Group (2017). Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Movement Disorders: Official Journal of the Movement Disorder Society, 32(6), 853–864. https://doi.org/10.1002/mds.26987
Lansdall, C. J., Coyle-Gilchrist, I. T. S., Jones, P. S., Vázquez Rodríguez, P., Wilcox, A., Wehmann, E., Dick, K. M., Robbins, T. W., & Rowe, J. B. (2017). Apathy and impulsivity in frontotemporal lobar degeneration syndromes. Brain: A Journal of Neurology, 140(6), 1792–1807. https://doi.org/10.1093/brain/awx101
Fenoglio, C., Scarpini, E., Serpente, M., & Galimberti, D. (2018). Role of genetics and epigenetics in the pathogenesis of Alzheimer's disease and frontotemporal dementia. Journal of Alzheimer's Disease: JAD, 62(3), 913–932. https://doi.org/10.3233/JAD-170702
Greaves, C. V., & Rohrer, J. D. (2019). An update on genetic frontotemporal dementia. Journal of Neurology, 266(8), 2075–2086. https://doi.org/10.1007/s00415-019-09363-4
Gossye, H., Engelborghs, S., Van Broeckhoven, C., & van der Zee, J. (2015). C9orf72 frontotemporal dementia and/or amyotrophic lateral sclerosis. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle. PMID: 25577942
Boeve, B. F., Boxer, A. L., Kumfor, F., Pijnenburg, Y., & Rohrer, J. D. (2022). Advances and controversies in frontotemporal dementia: Diagnosis, biomarkers, and therapeutic considerations. The Lancet. Neurology, 21(3), 258–272. https://doi.org/10.1016/S1474-4422(21)00341-0
Paushter, D. H., Du, H., Feng, T., & Hu, F. (2018). The lysosomal function of progranulin, a guardian against neurodegeneration. Acta Neuropathologica, 136(1), 1–17. https://doi.org/10.1007/s00401-018-1861-8
Yu, C. E., Bird, T. D., Bekris, L. M., Montine, T. J., Leverenz, J. B., Steinbart, E., Galloway, N. M., Feldman, H., Woltjer, R., Miller, C. A., Wood, E. M., Grossman, M., McCluskey, L., Clark, C. M., Neumann, M., Danek, A., Galasko, D. R., Arnold, S. E., Chen-Plotkin, A., Karydas, A., … Van Deerlin, V. M. (2010). The spectrum of mutations in progranulin: A collaborative study screening 545 cases of neurodegeneration. Archives of Neurology, 67(2), 161–170. https://doi.org/10.1001/ARCHNEUROL.2009.328
Hsiung, G. Y. R., & Feldman, H. H. (2007). GRN frontotemporal dementia. In M. P. Adam (Eds.) et. al., GeneReviews®. University of Washington, Seattle. PMID: 20301545
Benussi, A., Padovani, A., & Borroni, B. (2015). Phenotypic heterogeneity of monogenic frontotemporal dementia. Frontiers in Aging Neuroscience, 7, 171. https://doi.org/10.3389/fnagi.2015.00171
Mole S. E. (2004). The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathology (Zurich, Switzerland), 14(1), 70–76. https://doi.org/10.1111/j.1750-3639.2004.tb00500.x
Wang, Y., & Mandelkow, E. (2016). Tau in physiology and pathology. Nature Reviews. Neuroscience, 17(1), 5–21. https://doi.org/10.1038/nrn.2015.1
Yokoyama, J. S., Karch, C. M., Fan, C. C., Bonham, L. W., Kouri, N., Ross, O. A., Rademakers, R., Kim, J., Wang, Y., Höglinger, G. U., Müller, U., Ferrari, R., Hardy, J., International FTD-Genomics Consortium (IFGC), Momeni, P., Sugrue, L. P., Hess, C. P., James Barkovich, A., Boxer, A. L., Seeley, W. W., … Desikan, R. S. (2017). Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 133(5), 825–837. https://doi.org/10.1007/s00401-017-1693-y
Mann, D. M. A., & Snowden, J. S. (2017). Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathology (Zurich, Switzerland), 27(6), 723–736. https://doi.org/10.1111/bpa.12486
Klim, J. R., Pintacuda, G., Nash, L. A., Guerra San Juan, I., & Eggan, K. (2021). Connecting TDP-43 pathology with neuropathy. Trends in Neurosciences, 44(6), 424–440. https://doi.org/10.1016/j.tins.2021.02.008
Mackenzie, I. R., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M., & Lee, V. M. (2011). A harmonized classification system for FTLD-TDP pathology. Acta Neuropathologica, 122(1), 111–113. https://doi.org/10.1007/s00401-011-0845-8
Younes, K., & Miller, B. L. (2020). Frontotemporal dementia: Neuropathology, genetics, neuroimaging, and treatments. The Psychiatric Clinics of North America, 43(2), 331–344. https://doi.org/10.1016/j.psc.2020.02.006
Melamed, Z., López-Erauskin, J., Baughn, M. W., Zhang, O., Drenner, K., Sun, Y., Freyermuth, F., McMahon, M. A., Beccari, M. S., Artates, J. W., Ohkubo, T., Rodriguez, M., Lin, N., Wu, D., Bennett, C. F., Rigo, F., Da Cruz, S., Ravits, J., Lagier-Tourenne, C., & Cleveland, D. W. (2019). Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nature Neuroscience, 22(2), 180–190. https://doi.org/10.1038/s41593-018-0293-z
Goedert, M., Spillantini, M. G., Falcon, B., Zhang, W., Newell, K. L., Hasegawa, M., Scheres, S. H. W., & Ghetti, B. (2021). Tau protein and frontotemporal dementias. Advances in Experimental Medicine and Biology, 1281, 177–199. https://doi.org/10.1007/978-3-030-51140-1_12
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R., Lindholm, C., Snowden, J., Adamson, J., Sadovnick, A. D., Rollinson, S., Cannon, A., Dwosh, E., Neary, D., Melquist, S., Richardson, A., Dickson, D., Berger, Z., Eriksen, J., Robinson, T., Zehr, C., … Hutton, M. (2006). Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 442(7105), 916–919. https://doi.org/10.1038/nature05016
Elahi, F. M., & Miller, B. L. (2017). A clinicopathological approach to the diagnosis of dementia. Nature Reviews. Neurology, 13(8), 457–476. https://doi.org/10.1038/nrneurol.2017.96
Ishigaki, S., & Sobue, G. (2018). Importance of functional loss of FUS in FTLD/ALS. Frontiers in Molecular Biosciences, 5, 44. https://doi.org/10.3389/fmolb.2018.00044
Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H. A., & Mackenzie, I. R. (2009). A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain: A Journal of Neurology, 132(Pt 11), 2922–2931. https://doi.org/10.1093/brain/awp214
Bang, J., Spina, S., & Miller, B. L. (2015). Frontotemporal dementia. Lancet (London, England), 386(10004), 1672–1682. https://doi.org/10.1016/S0140-6736(15)00461-4
Katisko, K., Cajanus, A., Jääskeläinen, O., Kontkanen, A., Hartikainen, P., Korhonen, V. E., Helisalmi, S., Haapasalo, A., Koivumaa-Honkanen, H., Herukka, S. K., Remes, A. M., & Solje, E. (2020). Serum neurofilament light chain is a discriminative biomarker between frontotemporal lobar degeneration and primary psychiatric disorders. Journal of Neurology, 267(1), 162–167. https://doi.org/10.1007/s00415-019-09567-8
Illán-Gala, I., Lleo, A., Karydas, A., Staffaroni, A. M., Zetterberg, H., Sivasankaran, R., Grinberg, L. T., Spina, S., Kramer, J. H., Ramos, E. M., Coppola, G., La Joie, R., Rabinovici, G. D., Perry, D. C., Gorno-Tempini, M. L., Seeley, W. W., Miller, B. L., Rosen, H. J., Blennow, K., Boxer, A. L., … Rojas, J. C. (2021). Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology, 96(5), e671–e683. https://doi.org/10.1212/WNL.0000000000011226
Thijssen, E. H., La Joie, R., Strom, A., Fonseca, C., Iaccarino, L., Wolf, A., Spina, S., Allen, I. E., Cobigo, Y., Heuer, H., VandeVrede, L., Proctor, N. K., Lago, A. L., Baker, S., Sivasankaran, R., Kieloch, A., Kinhikar, A., Yu, L., Valentin, M. A., Jeromin, A., … Advancing Research and Treatment for Frontotemporal Lobar Degeneration investigators (2021). Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: A retrospective diagnostic performance study. The Lancet. Neurology, 20(9), 739–752. https://doi.org/10.1016/S1474-4422(21)00214-3
Scialò, C., Tran, T. H., Salzano, G., Novi, G., Caponnetto, C., Chiò, A., Calvo, A., Canosa, A., Moda, F., Caroppo, P., Silani, V., Ticozzi, N., Ratti, A., Borroni, B., Benussi, L., Ghidoni, R., Furlanis, G., Manganotti, P., Senigagliesi, B., Parisse, P., … Legname, G. (2020). TDP-43 real-time quaking induced conversion reaction optimization and detection of seeding activity in CSF of amyotrophic lateral sclerosis and frontotemporal dementia patients. Brain Communications, 2(2), fcaa142. https://doi.org/10.1093/braincomms/fcaa142
Zetterberg, H., van Swieten, J. C., Boxer, A. L., & Rohrer, J. D. (2019). Review: Fluid biomarkers for frontotemporal dementias. Neuropathology and Applied Neurobiology, 45(1), 81–87. https://doi.org/10.1111/nan.12530
Foster, N. L., Heidebrink, J. L., Clark, C. M., Jagust, W. J., Arnold, S. E., Barbas, N. R., DeCarli, C. S., Turner, R. S., Koeppe, R. A., Higdon, R., & Minoshima, S. (2007). FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain: A Journal of Neurology, 130(Pt 10), 2616–2635. https://doi.org/10.1093/brain/awm177
Ghirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., Labuzan, S. A., Spychalla, A. J., Pham, N. T. T., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Baker, M., Rademakers, R., Filippi, M., Jack, C. R., Jr, … Whitwell, J. L. (2020). Sensitivity-Specificity of tau and amyloid β positron emission tomography in frontotemporal lobar degeneration. Annals of Neurology, 88(5), 1009–1022. https://doi.org/10.1002/ana.25893
Tsai, R. M., Bejanin, A., Lesman-Segev, O., LaJoie, R., Visani, A., Bourakova, V., O'Neil, J. P., Janabi, M., Baker, S., Lee, S. E., Perry, D. C., Bajorek, L., Karydas, A., Spina, S., Grinberg, L. T., Seeley, W. W., Ramos, E. M., Coppola, G., Gorno-Tempini, M. L., Miller, B. L., … Rabinovici, G. D. (2019). 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimer's Research & Therapy, 11(1), 13. https://doi.org/10.1186/s13195-019-0470-7
Narayanan, L., & Murray, A. D. (2016). What can imaging tell us about cognitive impairment and dementia?. World Journal of Radiology, 8(3), 240–254. https://doi.org/10.4329/wjr.v8.i3.240
González-Caballero, G., Abellán-Miralles, I., & Sáenz-Sanjuan, M. J. (2015). Right temporal lobe variant of frontotemporal dementia. Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia, 22(7), 1139–1143. https://doi.org/10.1016/j.jocn.2014.12.022
Casaletto, K. B., Staffaroni, A. M., Wolf, A., Appleby, B., Brushaber, D., Coppola, G., Dickerson, B., Domoto-Reilly, K., Elahi, F. M., Fields, J., Fong, J. C., Forsberg, L., Ghoshal, N., Graff-Radford, N., Grossman, M., Heuer, H. W., Hsiung, G. Y., Huey, E. D., Irwin, D., Kantarci, K., … ARTFL/LEFFTDS Study (2020). Active lifestyles moderate clinical outcomes in autosomal dominant frontotemporal degeneration. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 16(1), 91–105. https://doi.org/10.1002/alz.12001
Bluett, B., Pantelyat, A. Y., Litvan, I., Ali, F., Apetauerova, D., Bega, D., Bloom, L., Bower, J., Boxer, A. L., Dale, M. L., Dhall, R., Duquette, A., Fernandez, H. H., Fleisher, J. E., Grossman, M., Howell, M., Kerwin, D. R., Leegwater-Kim, J., Lepage, C., Ljubenkov, P. A., … Golbe, L. I. (2021). Best practices in the clinical management of progressive supranuclear palsy and corticobasal syndrome: A consensus statement of the CurePSP centers of care. Frontiers in Neurology, 12, 694872. https://doi.org/10.3389/fneur.2021.694872
Henry, M. L., Meese, M. V., Truong, S., Babiak, M. C., Miller, B. L., & Gorno-Tempini, M. L. (2013). Treatment for apraxia of speech in nonfluent variant primary progressive aphasia. Behavioural Neurology, 26(1-2), 77–88. https://doi.org/10.3233/BEN-2012-120260
Dial, H. R., Hinshelwood, H. A., Grasso, S. M., Hubbard, H. I., Gorno-Tempini, M. L., & Henry, M. L. (2019). Investigating the utility of teletherapy in individuals with primary progressive aphasia. Clinical Interventions in Aging, 14, 453–471. https://doi.org/10.2147/CIA.S178878
Steffen, T. M., Boeve, B. F., Mollinger-Riemann, L. A., & Petersen, C. M. (2007). Long-term locomotor training for gait and balance in a patient with mixed progressive supranuclear palsy and corticobasal degeneration. Physical Therapy, 87(8), 1078–1087. https://doi.org/10.2522/ptj.20060166
Tanabe, H., Ikeda, M., & Komori, K. (1999). Behavioral symptomatology and care of patients with frontotemporal lobe degeneration - based on the aspects of the phylogenetic and ontogenetic processes. Dementia and Geriatric Cognitive Disorders, 10 Suppl 1, 50–54. https://doi.org/10.1159/000051213
Fick, W. F., van der Borgh, J. P., Jansen, S., & Koopmans, R. T. (2014). The effect of a lollipop on vocally disruptive behavior in a patient with frontotemporal dementia: A case-study. International Psychogeriatrics, 26(12), 2023–2026. https://doi.org/10.1017/S1041610214000866
Merrilees J. (2007). A model for management of behavioral symptoms in frontotemporal lobar degeneration. Alzheimer Disease and Associated Disorders, 21(4), S64–S69. https://doi.org/10.1097/WAD.0b013e31815bf774
Kales, H. C., Gitlin, L. N., Lyketsos, C. G., & Detroit Expert Panel on Assessment and Management of Neuropsychiatric Symptoms of Dementia (2014). Management of neuropsychiatric symptoms of dementia in clinical settings: Recommendations from a multidisciplinary expert panel. Journal of the American Geriatrics Society, 62(4), 762–769. https://doi.org/10.1111/jgs.12730
Shinagawa, S., Nakajima, S., Plitman, E., Graff-Guerrero, A., Mimura, M., Nakayama, K., & Miller, B. L. (2015). Non-pharmacological management for patients with frontotemporal dementia: A systematic review. Journal of Alzheimer's Disease: JAD, 45(1), 283–293. https://doi.org/10.3233/JAD-142109
Wong, C., Merrilees, J., Ketelle, R., Barton, C., Wallhagen, M., & Miller, B. (2012). The experience of caregiving: Differences between behavioral variant of frontotemporal dementia and Alzheimer disease. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 20(8), 724–728. https://doi.org/10.1097/JGP.0b013e318233154d
Samia, L. W., Aboueissa, A. M., Halloran, J., & Hepburn, K. (2014). The Maine savvy caregiver project: Translating an evidence-based dementia family caregiver program within the RE-AIM framework. Journal of Gerontological Social Work, 57(6-7), 640–661. https://doi.org/10.1080/01634372.2013.859201
Benussi, A., Dell'Era, V., Cosseddu, M., Cantoni, V., Cotelli, M. S., Cotelli, M., Manenti, R., Benussi, L., Brattini, C., Alberici, A., & Borroni, B. (2020). Transcranial stimulation in frontotemporal dementia: A randomized, double-blind, sham-controlled trial. Alzheimer's & Dementia (New York, N. Y.), 6(1), e12033. https://doi.org/10.1002/trc2.12033
Pressman, P. S., & Miller, B. L. (2014). Diagnosis and management of behavioral variant frontotemporal dementia. Biological Psychiatry, 75(7), 574–581. https://doi.org/10.1016/j.biopsych.2013.11.006
Boxer, A. L., Knopman, D. S., Kaufer, D. I., Grossman, M., Onyike, C., Graf-Radford, N., Mendez, M., Kerwin, D., Lerner, A., Wu, C. K., Koestler, M., Shapira, J., Sullivan, K., Klepac, K., Lipowski, K., Ullah, J., Fields, S., Kramer, J. H., Merrilees, J., Neuhaus, J., … Miller, B. L. (2013). Memantine in patients with frontotemporal lobar degeneration: A multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology, 12(2), 149–156. https://doi.org/10.1016/S1474-4422(12)70320-4
Herrmann, N., Black, S. E., Chow, T., Cappell, J., Tang-Wai, D. F., & Lanctôt, K. L. (2012). Serotonergic function and treatment of behavioral and psychological symptoms of frontotemporal dementia. The American Journal of Geriatric Psychiatry: Official Journal of the American Association for Geriatric Psychiatry, 20(9), 789–797. https://doi.org/10.1097/JGP.0b013e31823033f3
Sanchez, C., Reines, E. H., & Montgomery, S. A. (2014). A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?. International Clinical Psychopharmacology, 29(4), 185–196. https://doi.org/10.1097/YIC.0000000000000023
Tsai, R. M., & Boxer, A. L. (2014). Treatment of frontotemporal dementia. Current Treatment Options in Neurology, 16(11), 319. https://doi.org/10.1007/s11940-014-0319-0
Weiden P. J. (2007). EPS profiles: The atypical antipsychotics are not all the same. Journal of Psychiatric Practice, 13(1), 13–24. https://doi.org/10.1097/00131746-200701000-00003
Poetter, C. E., & Stewart, J. T. (2012). Treatment of indiscriminate, inappropriate sexual behavior in frontotemporal dementia with carbamazepine. Journal of Clinical Psychopharmacology, 32(1), 137–138. https://doi.org/10.1097/JCP.0b013e31823f91b9
Gálvez-Andres, A., Blasco-Fontecilla, H., González-Parra, S., Molina, J. D., Padín, J. M., & Rodriguez, R. H. (2007). Secondary bipolar disorder and Diogenes syndrome in frontotemporal dementia: Behavioral improvement with quetiapine and sodium valproate. Journal of Clinical Psychopharmacology, 27(6), 722–723. https://doi.org/10.1097/JCP.0b013e31815a57c1
Shinagawa, S., Tsuno, N., & Nakayama, K. (2013). Managing abnormal eating behaviours in frontotemporal lobar degeneration patients with topiramate. Psychogeriatrics: The Official Journal of the Japanese Psychogeriatric Society, 13(1), 58–61. https://doi.org/10.1111/j.1479-8301.2012.00429.x
Goforth, H. W., Konopka, L., Primeau, M., Ruth, A., O'Donnell, K., Patel, R., Poprawski, T., Shirazi, P., & Rao, M. (2004). Quantitative electroencephalography in frontotemporal dementia with methylphenidate response: A case study. Clinical EEG and Neuroscience, 35(2), 108–111. https://doi.org/10.1177/155005940403500212
Finger, E., Berry, S., Cummings, J., Coleman, K., Hsiung, R., Feldman, H. H., & Boxer, A. (2018). Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: A phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). Alzheimer's Research & Therapy, 10(1), 102. https://doi.org/10.1186/s13195-018-0427-2
O'Sullivan, S. S., Evans, A. H., & Lees, A. J. (2009). Dopamine dysregulation syndrome: An overview of its epidemiology, mechanisms and management. CNS Drugs, 23(2), 157–170. https://doi.org/10.2165/00023210-200923020-00005
Hinderer, C., Miller, R., Dyer, C., Johansson, J., Bell, P., Buza, E., & Wilson, J. M. (2020). Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations. Annals of Clinical and Translational Neurology, 7(10), 1843–1853. https://doi.org/10.1002/acn3.51165
Sevigny, J., Uspenskaya, O., Heckman, L. D., Wong, L. C., Hatch, D. A., Tewari, A., Vandenberghe, R., Irwin, D. J., Saracino, D., Le Ber, I., Ahmed, R., Rohrer, J. D., Boxer, A. L., Boland, S., Sheehan, P., Brandes, A., Burstein, S. R., Shykind, B. M., Kamalakaran, S., Daniels, C. W., … Hefti, F. (2024). Progranulin AAV gene therapy for frontotemporal dementia: Translational studies and phase 1/2 trial interim results. Nature Medicine, 30(5), 1406–1415. https://doi.org/10.1038/s41591-024-02973-0
Buccellato, F. R., D'Anca, M., Tartaglia, G. M., Del Fabbro, M., & Galimberti, D. (2024). Frontotemporal dementia: From genetics to therapeutic approaches. Expert Opinion on Investigational Drugs, 33(6), 561–573. https://doi.org/10.1080/13543784.2024.2349286
Rosbash M. (2020). Metformin treatment of the C9orf72 ALS/FTD mouse: Almost too good for words. Proceedings of the National Academy of Sciences of the United States of America, 117(33), 19627–19628. https://doi.org/10.1073/pnas.2012363117
Vaswani, P. A., & Olsen, A. L. (2020). Immunotherapy in progressive supranuclear palsy. Current Opinion in Neurology, 33(4), 527–533. https://doi.org/10.1097/WCO.0000000000000836
Gentry, E. G., Henderson, B. W., Arrant, A. E., Gearing, M., Feng, Y., Riddle, N. C., & Herskowitz, J. H. (2016). Rho kinase inhibition as a therapeutic for progressive supranuclear palsy and corticobasal degeneration. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience, 36(4), 1316–1323. https://doi.org/10.1523/JNEUROSCI.2336-15.2016
Novak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., Smisek, M., Hanes, J., Stevens, E., Kovac, A., Sutovsky, S., Parrak, V., Koson, P., Prcina, M., Galba, J., Cente, M., … Zilka, N. (2021). ADAMANT: A placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease. Nature Aging, 1(6), 521–534. https://doi.org/10.1038/s43587-021-00070-2
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Piotr Wilczkowski, Aleksandra Palka, Natalia Krzysztofek, Wojciech Kopyciński, Małgorzata Grzybowska, Katarzyna Boszczyk, Norbert Krawczyk, Monika Kamela, Adrianna Baran, Olaf Krawczyk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
